▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

GettyImages-1205778418

Aug 27, 2020 by Todd Campbell

Why Fulgent Genetics Is Crashing Today

Abbott's announcement of a new 15-minute COVID-19 test threatens recent revenue growth.

Aug 18, 2020 by Todd Campbell

Warren Buffett Just Bought These Stocks

Berkshire Hathaway's latest 13-F filing reveals interesting changes to his holdings.

GettyImages-1138911813

Aug 3, 2020 by Todd Campbell

Why Co-Diagnostics Skyrocketed 28.3% Today

The FDA has approved emergency use of its at-home COVID-19 test.

GettyImages-874899136

Jul 29, 2020 by Todd Campbell

Why Alector Is Tumbling 28.7% Today

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

GettyImages-1089374276

Jul 28, 2020 by Todd Campbell

Why Medpace Holdings Is Skyrocketing 13.5% Higher Today

The clinical trial company's second-quarter financial results were better than expected.

GettyImages-1186545957

Jul 22, 2020 by Todd Campbell

Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug

Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.

GettyImages-1138911813

Jul 22, 2020 by Todd Campbell

Why CytoSorbents Is Soaring 12% Today

The company has priced its recently announced stock offering.

GettyImages-996828576

Jul 21, 2020 by Todd Campbell

Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup

The biopharma giant is acquiring 49.9% of privately-held Tizona Therapeutics.

GettyImages-1205778418

Jul 21, 2020 by Todd Campbell

Here's Why OPKO Health's Stock Is Skyrocketing 23% Today

The company confirmed it will provide coronavirus testing for the National Football League.

GettyImages-910148024

Jul 16, 2020 by Todd Campbell

Here's Why Tricida Is Tanking 38.5% Today

The FDA has noted deficiencies in the application for approval of its only drug in development.

GettyImages-996828576

Jul 15, 2020 by Todd Campbell

Why Waters Stock Is Skyrocketing 12.9% Today

The healthcare company's second-quarter results appear better than expected.

vaccine

Jul 14, 2020 by Todd Campbell

Here's Why Dynavax Is Surging 6.1% Today

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.

GettyImages-637107694

Jul 14, 2020 by Todd Campbell

Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.

GettyImages-1138911813

Jul 13, 2020 by Todd Campbell

Why InMode Shares Are Soaring 13.7% Today

The medical device maker's boosting its second-quarter guidance.

GettyImages-1178374751

Jul 8, 2020 by Todd Campbell

Here's Why Retractable Technologies Is Skyrocketing 22% Today

The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.

GettyImages-1212440479

Jul 7, 2020 by Todd Campbell

GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.

GettyImages-637107694

Jul 7, 2020 by Todd Campbell

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

GettyImages-910148024

Jul 6, 2020 by Todd Campbell

Why Bellus Health Stock Tanked 69.2% Today

The company's lead drug has failed a phase 2 trial.

GettyImages-874899136

Jul 2, 2020 by Todd Campbell

Why MEI Pharma Is Tanking 15.3% Today

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.

GettyImages-1141354730

Jul 1, 2020 by Todd Campbell

Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Pfizer released intriguing data regarding its own COVID-19 vaccine.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services